Table 2 Treatment outcomes . CR Cri * .... | American Society of Hematology

Table 2

Treatment outcomes

	CR + Cri*		Time to event†
	CR (%)	CRi (%)	EFS (median, mo.)	OS (median, mo.)
All
CPX-351	41/84 (48.8)	15/84 (17.9)	6.5	14.7
7+3	20/41 (48.8)	1/41 (2.4)	2.0	12.9¶
High-risk‡
CPX-351	27/60 (45.0)	11/60 (18.3)	5.6	11.0
7+3	14/29 (48.3)	0	1.8	7.6¶
Cytogenetics
Adverse
CPX-351	11/22 (50.0)	6/22 (27.3)	7.8	10.6
7+3	5/13 (38.5)	0	1.1	12.2¶
Intermediate§
CPX-351	30/62 (48.4)	9/62 (14.5)	6.3	17.5
7+3	15/28 (53.4)	1/28 (3.6)	6.7	14.7¶
sAML
CPX-351	12/33 (36.7)	7/33 (21.2)	4.5	12.1TF2-5
7+3	6/19 (31.6)	0	1.3	6.1¶

	CR + Cri*		Time to event†
	CR (%)	CRi (%)	EFS (median, mo.)	OS (median, mo.)
All
CPX-351	41/84 (48.8)	15/84 (17.9)	6.5	14.7
7+3	20/41 (48.8)	1/41 (2.4)	2.0	12.9¶
High-risk‡
CPX-351	27/60 (45.0)	11/60 (18.3)	5.6	11.0
7+3	14/29 (48.3)	0	1.8	7.6¶
Cytogenetics
Adverse
CPX-351	11/22 (50.0)	6/22 (27.3)	7.8	10.6
7+3	5/13 (38.5)	0	1.1	12.2¶
Intermediate§
CPX-351	30/62 (48.4)	9/62 (14.5)	6.3	17.5
7+3	15/28 (53.4)	1/28 (3.6)	6.7	14.7¶
sAML
CPX-351	12/33 (36.7)	7/33 (21.2)	4.5	12.1TF2-5
7+3	6/19 (31.6)	0	1.3	6.1¶

One patient was removed from the CPX-351 group before response assessment to be treated with imatinib.

Twenty-four-month data.

High-risk defined as sAML or adverse cytogenetics or ≥70 years of age.

Includes unknown and favorable cytogenetics.

Includes patients that crossed over to CPX-351.